A PAF antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep.
We studied the effects of WEB-2086, a specific antagonist of platelet-activating factor (PAF), on the development of antigen-induced airway hyperresponsiveness and inflammation in sheep (n = 8). For these studies, airway responsiveness was determined from slopes of carbachol dose-response curves (DRC) performed at base line (prechallenge) and 2 h after Ascaris suum antigen challenges in the following three protocols: 1) antigen challenge alone (control trial), 2) WEB-2086 (1 mg/kg iv) given 30 min before antigen challenge (WEB pretreatment), and 3) WEB-2086 given 2 h after antigen challenge, immediately before the postchallenge DRC (WEB posttreatment). Airway inflammation was assessed by bronchoalveolar lavage (BAL) before antigen challenge and after the postchallenge DRC for each trial. A. suum challenge resulted in acute increases in specific lung resistance that were not different among the three trials. Antigen challenge (control trial) caused a 93% increase (P less than 0.05) in the slope of the carbachol DRC when compared with the prechallenge value. WEB pretreatment (1 mg/kg) reduced (P less than 0.05) this antigen-induced hyperresponsiveness, whereas pretreatment with a 3-mg/kg dose completely prevented it. WEB posttreatment was ineffective in blocking this hyperresponsiveness. BAL neutrophils increased after antigen challenge in the control trial and when WEB-2086 was given after antigen challenge (P less than 0.05). Pretreatment with WEB-2086 (1 or 3 mg/kg) prevented this neutrophilia. This study provides indirect evidence for antigen-induced PAF release in vivo and for a role of endogenous PAF in the modulation of airway responsiveness and airway inflammation after antigen-induced bronchoconstriction in sheep.
Division of Pulmonary Disease, Mount Sinai Medical Center, Miami Beach, Florida 33140.
M
M
Solèr
M W
MW
Sielczak
W M
WM
Abraham
D000403:Airway Resistance / Q000187:drug effects*; D000818:Animals; D000947:Antigens, Helminth / Q000276:immunology*; D001200:Ascaris / Q000276:immunology*; D001381:Azepines / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis; D002217:Carbachol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D012130:Respiratory Hypersensitivity / Q000276:immunology* / Q000503:physiopathology; D012756:Sheep; D014227:Triazines / Q000494:pharmacology*; D014230:Triazoles
D000947:Antigens, Helminth; D001381:Azepines; D010972:Platelet Activating Factor; D014227:Triazines; D014230:Triazoles; C052518:WEB 2086; D002217:Carbachol